The safety of etanercept for the treatment of plaque psoriasis

Therapeutics and Clinical Risk Management

Volumn 3, Issue 2, 2007, Pages 245-258

  Papp, Kim A ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Demyelination; Etanercept; Infection; Lymphoma; Psoriasis; Safety; Tuberculosis; Tumor necrosis factor

Indexed keywords

ANTIBIOTIC AGENT; ETANERCEPT; INFLIXIMAB; INFLUENZA VACCINE; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; VACCINE;

APLASTIC ANEMIA; BONE MARROW SUPPRESSION; BREAST FEEDING; CHRONIC INFLAMMATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CUTANEOUS T CELL LYMPHOMA; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DIABETES MELLITUS; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MILK LEVEL; DRUG RESPONSE; DRUG SAFETY; HEPATITIS B; HEPATITIS C; HISTOPLASMOSIS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INCIDENCE; INFECTION; INJECTION SITE IRRITATION; INJECTION SITE REACTION; INSULIN RESISTANCE; LEUKOCYTOCLASTIC VASCULITIS; LISTERIOSIS; LOW DRUG DOSE; LUPUS LIKE SYNDROME; LYMPHOCYTE; LYMPHOMA; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE SCLEROSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PANCYTOPENIA; PATIENT MONITORING; PREGNANCY; PSORIASIS; PSORIASIS VULGARIS; REVIEW; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; SCREENING TEST; SEPTICEMIA; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SPOROTRICHOSIS; T CELL LYMPHOMA; TUBERCULOSIS; URTICARIA; VACCINATION; WOUND HEALING;

EID: 34249978145     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2007.3.2.245     Document Type: Review

References (204)

1. Abel L, Casanova JL. 2000. Genetic predisposition to clinical tuberculosis: bridging the gap between simple and complex inheritance. Am J Hum Genet, 67:274-7.
2. Adams AE, Zwicker J, Curiel C, et al. 2004. Aggressive cutaneous T-cell lymphomas after TNFalpha blockade. J Am Acad Dermatol, 51:660-2.
3. Arend SM, Breedveld FC, van Dissel JT. 2003. TNF-alpha blockade and tuberculosis: better look before you leap. Neth J Med, 61:111-19.
4. Arnott CH, Scott KA, Moore RJ, et al. 2002. Tumour necrosis factor-alpha mediates tumour promotion via a PKC alpha- and AP-1-dependent pathway. Oncogene, 21:4728-38.
5. Arunkumar P, Crook T, Ballard J. 2004. Disseminated histoplasmosis presenting as pancytopenia in a methotrexate-treated patient. Am J Hematol, 77:86-7.
6. Baecklund E, Askling J, Rosenquist R, et al. 2004. Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol, 16:254-61.
7. Baecklund F, Ekbom A, Sparen P, et al. 1998. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ, 317:180-1.
8. Baecklund E, Iliadou A, Askling J, et al. 2006. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum, 54:692-701.
9. Baecklund E, Sundstrom C, Ekbom A, et al. 2003. Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. Arthritis Rheum, 48:1543-50.
10. Baghai M, Osmon DR, Wolk DM, et al. 2001. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc, 76:653-6.
11. Balkwill FR, Naylor MS, Malik S. 1990. Tumour necrosis factor as an anticancer gent. Eur J Cancer, 26:641-4.
12. Baran-Marszak F, Laguillier C, Youlyouz I, et al. 2006. Effect of tumor necrosis factor alpha and infliximab on apoptosis of B lymphocytes infected or not with Epstein-Barr virus. Cytokine, 33:337-45.
13. Baumelou E, Guiguet M, Mary JY. 1993. Epidemiology of aplastic anemia in France: a case-control study. I. Medical history and medication use. The French Cooperative Group for Epidemiological Study of Aplastic Anemia. Blood, 81:1471-8.
14. Bellesi M, Logullo F, Di Bella P, et al. 2006. CNS demyelination during anti-tumor necrosis factor alpha therapy. J Neurol, 253:668-9.
15. Berry CL. 1969. Modification of the host response in experimental histoplasmosis. J Pathol, 97:653-64.
16. Bibbo C, Goldberg JW. 2004. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int, 25:331-5.
17. Bleumink GS, Ter Borg EJ, Ramselaar CG, et al. 2001. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford), 40:1317-19.
18. Botha T, Ryffel B. 2003. Reactivation of latent tuberculosis infection in TNF-deficient mice. J Immunol, 171:3110-18.
19. Bozkurt B, Torre-Amione G, Warren MS, et al. 2001. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation, 103:1044-7.
20. Brown SL, Greene MH, Gershon SK, et al. 2002. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum, 46:3151-8.
21. Cairns AP, Duncan MK, Hinder AE, et al. 2002. New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis, 61:1031-2.
22. Calabrese LH, Zein N, Vassilopoulos D. 2004. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis, 63(Suppl 2):ii18-24.
23. Cano MV, Hajjeh RA. 2001. The epidemiology of histoplasmosis: a review. Semin Respir Infect, 16:109-18.
24. Carlson E, Rothfield N. 2003. Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum, 48:1165-6; author reply 1166.
25. Casanova JL, Abel L. 2002. Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol, 20:581-620.
26. Catrina AI, Trollmo C, Af Klint E, et al. 2005. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum, 52:61-72.
27. [CDC] Centers for Disease Control and Prevention. 2004. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha - California, 2002-2003. MMWR Morb Mortal Wkly Rep, 53:683-6.
28. Chang ET, Smedby KE, Hjalgrim H, et al. 2005. Medication use and risk of non-Hodgkin's lymphoma. Am J Epidemiol, 162:965-74.
29. Choy EH, Panayi GS. 2001. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med, 344:907-16.
30. Cisternas M, Gutierrez M, Jacobelli S. 2002. Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al. Arthritis Rheum, 46:3107-8; author reply 3108-9.
31. Creasey AA, Reynolds MT, Laird W. 1986. Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor. Cancer Res, 46:5687-90.
32. Cush JJ. 2004a. Safety of new biologic therapies in rheumatoid arthritis. Bulletin on the Rheumatic Diseases, 2:1-7.
33. Cush JJ. 2004b. Safety overview of new disease-modifying antirheumatic drugs. Rheum Dis Clin North Am, 30:237-55, v.
34. Cush JJ. 2004c. Unusual toxicities with TNF inhibition: heart failure and drug-induced lupus. Clin Exp Rheumatol, 22:S141-7.
35. Daher S, Fonseca F, Ribeiro OG, et al. 1999. Tumor necrosis factor during pregnancy and at the onset of labor and spontaneous abortion. Eur J Obstet Gynecol Reprod Biol, 83:77-9.
36. Debandt M, Sibilia J, Le Loet X, et al. 2005. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther, 7:R545-51.
37. De Franchis R, Hadengue A, Lau G, et al. 2003. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol, 39(Suppl 1):S3-25.
38. Debandt M, Vittecoq O, Descamps V, et al. 2003. Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol, 22:56-61.
39. Dembic Z, Loetscher H, Gubler U, et al. 1990. Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. Cytokine, 2:231-7.
40. Dinarello CA. 2003. Anti-cytokine therapeutics and infections. Vaccine, 21(Suppl 2):S24-34.
41. Dinarello CA. 2005. Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment. J Rheumatol Suppl, 74:40-7.
42. Doran MF, Crowson CS, Pond GR, et al. 2002a. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum, 46:2287-93.
43. Doran MF, Crowson CS, Pond GR, et al. 2002b. Predictors of infection in rheumatoid arthritis. Arthritis Rheum, 46:2294-300.
44. Dye C, Scheele S, Dolin P, et al. 1999. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA, 282:677-86.
45. Ebers GC, Sadovnick AD. 1993. The geographic distribution of multiple sclerosis: a review. Neuroepidemiology, 12:1-5.
46. Edwards KR, Mowad CM, Tyler WB. 2003. Worsening injection site reactions with continued use of etanercept. J Drugs Dermatol, 2:184-7.
47. Ehlers S. 2005. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis, 41(Suppl 3):S199-203.
48. Ehlers S, Holscher C, Scheu S, et al. 2003. The lymphotoxin beta receptor is critically involved in controlling infections with the intracellular pathogens Mycobacterium tuberculosis and Listeria monocytogenes. J Immunol, 170:5210-18.
49. Ekstrom K, Hjalgrim H, Brandt L, et al. 2003. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum, 48:963-70.
50. Elahi MM, Matata BM. 2005. Genetic diversity of tumour necrosis factor: implications on cardiovascular complications of polymorphisms at position -308 in the promoter region. The Cardiology, 1:179-88.
51. Elkayam O, Caspi D, Reitblatt T, et al. 2004. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum, 33:283-8.
52. [FDA] Food and Drug Administration Briefing Document. 2003. Update on the TNF-blocking agents [online]. Acessed on 22 October 2006. URL: http://www.fda.gov/ohrms/dockets/ac/03/briefing/ 3930B1_01_B-TNF.Briefing.pdf.
53. Filella X, Blade J, Guillermo AL, et al. 1996. Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma. Cancer Detect Prev, 20:52-6.
54. Fisher CJ Jr, Agosti JM, Opal SM, et al. 1996. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med, 334:1697-702.
55. Fleischmann R, Yocum D. 2004. Does safety make a difference in selecting the right TNF antagonist? Arthritis Res Ther, 6(Suppl 2):S12-18.
56. Fomin I, Caspi D, Levy V, et al. 2006. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis, 65:191-4.
57. Freedman MH, Cohen A, Grunberger T, et al. 1992. Central role of tumour necrosis factor, GM-CSF, and interleukin 1 in the pathogenesis of juvenile chronic myelogenous leukaemia. Br J Haematol, 80:40-8.
58. Galaria NA, Werth VP, Schumacher HR. 2000. Leukocytoclastic vasculitis due to etanercept. J Rheumatol, 27:2041-4.
59. Gardam MA, Keystone EC, Menzies R, et al. 2003. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis, 3:148-55.
60. Garrison L, McDonnell ND. 1999. Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis, 58(Suppl 1):I65-9.
61. Gelfand JM, Berlin J, van Voorhees A, et al. 2003. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol, 139:1425-9.
62. Gelfamd JM, Shin DB, Neimann AL, et al. 2006. The risk of lymphoma in patients with psoriasis. J Invest Dermatol.
63. Gottlieb GS, Lesser CF, Holmes KK, et al. 2003. Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists. Clin Infect Dis, 37:838-40.
64. Gruss HJ, Dower SK. 1995. The TNF ligand superfamily and its relevance for human diseases. Cytokines Mol Ther, 1:75-105.
65. Hamon M, Bierne H, Cossart P. 2006. Listeria monocytogenes: a multifaceted model. Nat Rev Microbiol, 4:423-34.
66. HAMOSH, M. 1996. Digestion in the newborn. Clin Perinatol, 23:191-209.
67. Han S, Zhang X, Marinova E, et al. 2005. Blockade of lymphotoxin pathway exacerbates autoimmune arthritis by enhancing the Th1 response. Arthritis Rheum, 52:3202-9.
68. Hannuksela-Svahn A, Pukkala E, Laara E, et al. 2000. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol, 114:587-90.
69. Haraoui B, Keystone E. 2006. Musculoskeletal manifestations and autoimmune diseases related to new biologic agents. Curr Opin Rheumatol, 18:96-100.
70. Havell EA. 1989. Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol, 143:2894-9.
71. Hellmich B, Lamprecht P, Gross WL. 2006. Advances in the therapy of Wegener's granulomatosis. Curr Opin Rheumatol, 18:25-32.
72. Henderson TR, Hamosh M, Armand M, et al. 2001. Gastric proteolysis in preterm infants fed mother's milk or formula. Adv Exp Med Biol, 501:403-8.
73. Herbein G, O'Brien WA. 2000. Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc Soc Exp Biol Med, 223:241-57.
74. Hermoso MA, Matsuguchi T, Smoak K, et al. 2004. Glucocorticoids and tumor necrosis factor alpha cooperatively regulate toll-like receptor 2 gene expression. Mol Cell Biol, 24:4743-56.
75. HPB Canada. 2006. Dear Healthcare Professional Letter (2006 Jan 18) [online]. Accessed on 15 December 2006. URL: http:/www.hc-sc.gc.ca/ dhp-mps/medeff/advisories-avis/public/2006/anti-tnf_therapy_prcp_e.html.
76. Imanishi J. 2000. Expression of cytokines in bacterial and viral infections and their biochemical aspects. J Biochem (Tokyo), 127:525-30.
77. Imperato AK, Smiles S, Abramson SB. 2004. Long-term risks associated with biologic response modifiers used in rheumatic diseases. Curr Opin Rheumatol, 16:199-205.
78. Ioannidis JP, Mulrow CD, Goodman SN. 2006. Adverse events: the more you search, the more you find. Ann Intern Med, 144:298-300.
79. Jarvis B, Faulds D. 1999. Etanercept: a review of its use in rheumatoid arthritis. Drugs, 57:945-66.
80. Jasmer RM, Nahid P, Hopewell PC. 2002. Clinical practice. Latent tuberculosis infection. N Engl J Med, 347:1860-6.
81. Jonsdottir T, Forslid J, van Vollenhoven A, et al. 2004. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis, 63:1075-8.
82. Kanaly ST, Nashleanas M, Hondowicz B, et al. 1999. TNF receptor p55 is required for elimination of inflammatory cells following control of intracellular pathogens. J Immunol, 163:3883-9.
83. Kapetanovic MC, Saxne T, Sjoholm A, et al. 2006. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford), 45:106-11.
84. Kato I, Koenig KL, Baptiste MS, et al. 2003. History of antibiotic use and risk of non-Hodgkin's lymphoma (NHL). Int J Cancer, 107:99-105.
85. Kavanaugh A, Tutuncu Z, Catalan-Sanchez T. 2006. Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis. Curr Opin Rheumatol, 18:347-53.
86. Keane J. 2004. Tumor necrosis factor blockers and reactivation of latent tuberculosis. Clin Infect Dis, 39:300-2.
87. Keane J. 2005. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford), 44:714-20.
88. Keane J, Gershon S, Wise RP, et al. 2001. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med, 345:1098-104.
89. Keystone EC. 2004. Safety issues related to emerging therapies for rheumatoid arthritis. Clin Exp Rheumatol, 22:S148-50.
90. Keystone EC. 2005. Safety of biologic therapies - an update. J Rheumatol Suppl, 74:8-12.
91. Keystone EC, Dinarello CC. 2005. Mechanism of action of tumor necrosis factor antagonists. J Rheumatol Suppl, 74:1-2.
92. Khan G. 2006. Epstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin's lymphoma? Exp Hematol, 34:399-406.
93. Khanna D, McMahon M, Furst DE. 2004. Safety of tumour necrosis factor-alpha antagonists. Drug Saf, 27:307-24.
94. Khanna M, Shirodkar MA, Gottlieb AB. 2003. Etanercept therapy in patients with autoimmunity and hepatitis C. J Dermatolog Treat, 14:229-32.
95. Koller H, Kieseier BC, Jander S, et al. 2005a. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med, 352:1343-56.
96. Koller H, Schroeter M, Kieseier BC, et al. 2005b. Chronic inflammatory demyelinating polyneuropathy - update on pathogenesis, diagnostic criteria and therapy. Curr Opin Neurol, 18:273-8.
97. Korth-Bradley JM, Rubin AS, Hanna RK, et al. 2000. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother, 34:161-4.
98. Krishnan E, Fries JF. 2004. Measuring effectiveness of drugs in observational databanks: promises and perils. Arthritis Res Ther, 6:41-4.
99. Kwon HJ, Cote TR, Cuffe MS, et al. 2003. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med, 138:807-11.
100. La Montagna G, Vatentini G. 2005. Listeria monocytogenes meningitis in a patient receiving etanercept for Still's disease. Clin Exp Rheumatol, 23:121.
101. Lebwohl M. 2002. New developments in the treatment of psoriasis. Arch Dermatol, 138:686-8.
102. Lee JH, Slifman NR, Gershon SK, et al. 2002. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum, 46:2565-70.
103. Lemense GP, Sahn SA. 1994. Opportunistic infection during treatment with low dose methotrexate. Am J Respir Crit Care Med, 150:258-60.
104. Leonardi CL, Powers JL, Matheson RT, et al. 2003. Etanercept as monotherapy in patients with psoriasis. N Engl J Med, 349:2014-22.
105. Liebowitz D. 1998. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med, 338:1413-21.
106. Listing J, Strangfeld A, Kary S, et al. 2005. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum, 52:3403-12.
107. Liz-Grana M, Gomez-Reino Carnota JJ. 2001. Tumour necrosis factor. genetics, cell action mechanism and involvement in inflammation. Alergol Immunol Clin, 16:140-9.
108. [LMS-UBC] The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. 1999. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology, 53:457-65.
109. Lok AS, McMahon BJ. 2004. Chronic hepatitis B: update of recommendations. Hepatology, 39:857-61.
110. Luheshi GN, Stefferl A, Turnbull AV, et al. 1997. Febrile response to tissue inflammation involves both peripheral and brain IL-1 and TNF-alpha in the rat. Am J Physiol, 272:R862-8.
111. Magnano MD, Robinson WH, Genovese MC. 2004. Demyelination and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol, 22: S134-40.
112. Malik ST, Naylor MS, East N, et al. 1990. Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. Eur J Cancer, 26:1031-4.
113. Mann DL, McMurray JJ, Packer M, et al. 2004. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation, 109:1594-602.
114. Marino MW, Dunn A, Grail D, et al. 1997. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA, 94:8093-8.
115. Marshall RW, Marshall VJ, Hull R. 2006. Disease-modifying anti-rheumatic drugs are only one of a number of potential causes of myelosuppression: a careful drug history is necessary to elucidate the cause of an adverse event. Rheumatology (Oxford), 45:362-3; author reply 363-4.
116. Mease PJ, Goffe BS, Metz J, et al. 2000. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet, 356:385-90.
117. Meyer RM, Ambinder RF, Stroobants S. 2004. Hodgkin's lymphoma: evolving concepts with implications for practice. Hematology (Am Soc Hematol Educ Program) 184-202.
118. Michel M, Duvoux C, Hezode C, et al. 2003. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol, 30:1624-5.
119. Midgard R, Gronning M, Riise T, et al. 1996. Multiple sclerosis and chronic inflammatory diseases. A case-control study. Acta Neurol Scand, 93:322-8.
120. Misery L, Perrot JL, Gentil-Perret A, et al. 2002. Dermatological complications of etanercept therapy for rheumatoid arthritis. Br J Dermatol, 146:334-5.
121. Mitsos LM, Cardon LR, Ryan L, et al. 2003. Susceptibility to tuberculosis: a locus on mouse chromosome 19 (Trl-4) regulates Mycobacterium tuberculosis replication in the lungs. Proc Natl Acad Sci U S A, 100:6610-15.
122. Mohan AK, Edwards ET, Cote TR, et al. 2002. Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet, 360:646.
123. Mohan N, Edwards ET, Cupps TR, et al. 2001. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum, 44:2862-9.
124. Mohan N, Edwards ET, Cupps TR, et al. 2004. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol, 31:1955-8.
125. Mohler KM, Torrance DS, Smith CA, et al. 1993. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol, 151:1548-61.
126. Moore RJ, Owens DM, Stamp G, et al. 1999. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med, 5:828-31.
127. Moore TA, Lau HY, Cogen AL, et al. 2003. Anti-tumor necrosis factor-alpha therapy during murine Kiebsiella pneumoniae bacteremia: increased mortality in the absence of liver injury. Shock, 20:309-15.
128. Moore TA, Lau HY, Cogen AL, et al. 2005. Defective innate antibacterial host responses during murine Kiebsiella pneumoniae bacteremia: tumor necrosis factor (TNF) receptor 1 deficiency versus therapy with antiTNF-alpha. Clin Infect Dis, 41 (Suppl 3):S213-l7.
129. Mukhtyar C, Luqmani R. 2005. Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis. Ann Rheum Dis, 64(Suppl 4):iv31-6.
130. Mulrow C, Langhorne P, Grimshaw J. 1997. Integrating heterogeneous pieces of evidence in systematic reviews. Ann Intern Med, 127:989-95.
131. Murakami T, Okamura C, Matsuzaki S, et al. 2002. Prediction of pregnancy in infertile women with endometriosis. Gynecol Obstet Invest, 53(Suppl 1):26-32.
132. Nadarajah K, Pritchard C. 2005. Listeria monocytogenes septic arthritis in a patient treated with etanercept for rheumatoid arthritis. J Clin Rheumatol, 11:120-2.
133. Netea MG, Radstake T, Joosten LA, et al. 2003. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum, 48:1853-7.
134. O'Brien DP, Briles DE, Szalai AJ, et al. 1999. Tumor necrosis factor alpha receptor I is important for survival from Streptococcus pneumoniae infections. Infect Immun, 67:595-601.
135. Obayashi H, Hasegawa G, Fukui M, et al. 2000. Tumor necrosis factor microsatellite polymorphism influences the development of insulin dependency in adult-onset diabetes patients with the DRB1*1502-DQB1*0601 allele and anti-glutamic acid decarboxylase antibodies. J Clin Endocrinol Metab, 85:3348-51.
136. Old LJ. 1985. Tumor necrosis factor (TNF). Science, 230:630-2.
137. Olleros ML, Guler R, Vesin D, et al. 2005. Contribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis bacillus Calmette-guerin and Mycobacterium tuberculosis infections. Am J Pathol, 166:1109-20.
138. Ostensen M, Eigenmann GO. 2004. Etanercept in breast milk. J Rheumatol, 31:1017-18.
139. Ostuni P, Botsios C, Punzi L, et al. 2003. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis, 62:686-7.
140. Pagliano P, Attanasio V, Fusco U, et al. 2004. Does etanercept monotherapy enhance the risk of Listeria monocytogenes meningitis? Ann Rheum Dis, 63:462-3.
141. Palladino MA Jr, Patton JS, Figari IS, et al. 1987. Possible relationships between in vivo antitumour activity and toxicity of tumour necrosis factor-alpha. Ciba Found Symp, 131:21-38.
142. Palladino MA Jr, Srivastava PK, Oettgen HF, et al. 1987. Expression of a shared tumor-specific antigen by two chemically induced BALB/c sarcomas. Cancer Res, 47:5074-9.
143. Papp KA. 2004. Etanercept in psoriasis. Expert Opin Pharmacother, 5:2139-46.
144. Papp KA, Tyring S, Lahfa M, et al. 2005. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol, 152:1304-12.
145. Peterson JR, Hsu FC, Simkin PA, et al. 2003. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis, 62:1078-82.
146. Pfeffer K. 2003. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev, 14:185-91.
147. Poppema S. 2005. Immunobiology and pathophysiology of hodgkin lymphomas. Hematology (Am Soc Hematol Educ Program):231-8.
148. Rachapalli S, O'Daunt S. 2005. Septic arthritis due to Listeria monocytogenes in a patient receiving etanercept. Arthritis Rheum, 52:987.
149. Rajalculendran S, Deighton C. 2004. Delayed multiple injection site reaction in a rheumatoid arthritis patient treated with etanercept. Rheumatology (Oxford), 43:1588-9.
150. Rasmussen SK, Urhammer SA, Jensen JN, et al. 2000. The -238 and -308 G->A polymorphisms of the tumor necrosis factor alpha gene promoter are not associated with features of the insulin resistance syndrome or altered birth weight in Danish Caucasians. J Clin Endocrinol Metab, 85:1731-4.
151. Renard N, Ribeiro P, Warzocha K, et al. 1999. Modulation of costimulatory molecules on follicular lymphoma cells by TNF and CD40. Leuk Lymphoma, 33:331-41.
152. Rickinson AB, Kieff E. 1996. Epstein-Barr virus. In: Knipe DM, Howley PM (Eds.) Virology. Philadelphia, Lippincott-Raven.
153. Rijneveld AW, Florquin S. Hartung T, et al. 2003. Anti-tumor necrosis factor antibody impairs the therapeutic effect of ceftriaxone in murine pneumococcal pneumonia. J Infect Dis, 188:282-5.
154. Roach DR, Bean AG, Demangel C, et al. 2002. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol, 168:4620-7.
155. Rothe J, Lesslauer W, Lotscher H, et al. 1993. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature, 364:798-802.
156. Roy V, Hammerschmidt DE. 2000. Disseminated histoplasmosis following prolonged low-dose methotrexate therapy. Am J Hematol, 63:59-60.
157. Sadovnick AD, Armstrong H, Rice GP, et al. 1993. A population-based study of multiple sclerosis in twins: update. Ann Neurol, 33:281-5.
158. Saunders BM, Tran S, Ruuls S, et al. 2005. Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. J Immunol, 174:4852-9.
159. Schett G, Herak P, Graninger W, et al. 2005. Listeria-associated arthritis in a patient undergoing etanercept therapy: case report and review of the literature. J Clin Microbiol, 43:2537-41.
160. Schiemann U, Kellner H. 2002. Gastrointestinal side effects in the therapy of rheumatologic diseases. Z Gastroenterol, 40:937-43.
161. Schlaak JF, Tully G, Lohr HF, et al. 1999. HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines. Clin Exp Immunol, 115:508-14.
162. Sfikakis PP, Iliopoulos A, Elezoglou A, et al. 2005. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum, 52:2513-18.
163. Shakoor N, Michalska M, Harris CA, et al. 2002. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet, 359:579-80.
164. Shepherd GM. 2003. Hypersensitivity reactions to drugs: evaluation and management. Mt Sinai J Med, 70:113-25.
165. Skytta E, Pohjankoski H, Savolainen A. 2000. Etanercept and urticaria in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol, 18:533-4.
166. Slifman NR, Gershon SK, Lee JH, et al. 2003. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum, 48:319-24.
167. Smedby KE, Hjalgrim H, Askling J, et al. 2006. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst, 98:51-60.
168. Smith JG, Magee DM, Williams DM, et al. 1990. Tumor necrosis factor-alpha plays a role in host defense against Histoplasma capsulatum. J Infect Dis, 162:1349-53.
169. Smith KJ, Skelton HG. 2001. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol, 45:953-6.
170. Sokka T. 2004. Rheumatoid arthritis databases. Rheum Dis Clin North Am, 30:769-81, vi.
171. Spahn TW, Eugster HP, Fontana A, et al. 2005. Role of lymphotoxin in experimental models of infectious diseases: potential benefits and risks of a therapeutic inhibition of the lymphotoxin-beta receptor pathway. Infect Immun, 73:7077-88.
172. Stefferl A, Hopkins SJ, Rothwell NJ, et al. 1996. The role of TNF-alpha in fever: opposing actions of human and murine TNF-alpha and interactions with IL-beta in the rat. Br J Pharmacol, 118:1919-24.
173. Stenger S. 2005. Immunological control of tuberculosis: role of tumour necrosis factor and more. Ann Rheum Dis, 64(Suppl 4):iv24-8.
174. Stone JH, Holbrook JT, Marriott MA, et al. 2006. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum, 54:1608-18.
175. Sukal SA, Nadiminti L, Granstein RD. 2006. Etanercept and demyelinating disease in a patient with psoriasis. J Am Acad Dermatol, 54:160-4.
176. Takashima K, Tateda K, Matsumoto T, et al. 1997. Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice. Infect Immun, 65:257-60.
177. Tartakovsky B, Ben-Yair E. 1991. Cytokines modulate preimplantation development and pregnancy. Dev Biol, 146:345-52.
178. Torre-Amione G, Vooletich MT, Farmer JA. 2000. Role of tumour necrosis factor-alpha in the progression of heart failure: therapeutic implications. Drugs, 59:745-51.
179. Torres D, Janot L, Quesniaux VF, et al. 2005. Membrane tumor necrosis factor confers partial protection to Listeria infection. Am J Pathol, 167:1677-87.
180. Turnbull AV, Rivier CL. 1999. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev, 79:1-71.
181. Tyring S, Gottlieb A, Papp K, et al. 2006. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet, 367:29-35.
182. Van Oosten BW, Barkhof F, Truyen L, et al. 1996. Increased MRI activity and immune activatin in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology, 47:1531-4.
183. Voloshin DK, Lacomis D, McMahon D. 1995. Disseminated histoplasmosis presenting as myositis and fasciitis in a patient with dermatomyositis. Muscle Nerve, 18:531-5.
184. Wallis RS, Broder M, Wang J, et al. 2004a. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis, 39:1254-5.
185. Wallis RS, Broder MS, Wong JY, et al. 2004b. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis, 38:1261-5.
186. Warzocha K, Bienvenu I, Coiffier B, et al. 1995. Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system. Eur Cytokine Netw, 6:83-96.
187. Warzocha K, Bienvenu J, Ribeiro P, et al. 1998. Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients. Br J Cancer, 77:2357-62.
188. Warzocha K, Ribeiro P, Bienvenu J, et al. 1998. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood, 91:3574-81.
189. Warzocha K, Salles G. 1998. The tumor necrosis factor signaling complex: choosing a path toward cell death or cell proliferation. Leuk Lymphoma, 29:81-92.
190. Watts RA. 2000. Musculoskeletal and systemic reactions to biological therapeutic agents. Curr Opin Rheumatol, 12:49-52.
191. Werth VP, Levinson AI. 2001. Etanercept-induced injection site reactions: mechanistic insights from clinical findings and immunohistochemistry. Arch Dermatol, 137:953-5.
192. Weyand CM, Goronzy JJ, Kurtin PJ. 2006. Lymphoma in rheumatoid arthritis: an immune system set up for failure. Arthritis Rheum, 54:685-9.
193. [WGET] Wegener's Granulomatosis Etanercept Trial Research Group. 2005.
194. Wiendl H, Hohlfeld R. 2002. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs, 16:183-200.
195. Williams JD, Griffiths CE. 2002. Cytokine blocking agents in dermatology. Clin Exp Dermatol, 27:585-90.
196. Witty LA, Steiner F, Curfman M, et al. 1992. Disseminated histoplasmosis in patients receiving low-dose methotrexate therapy for psoriasis. Arch Dermatol, 128:91-3.
197. Wolfe F, Michaud K. 2004a. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med, 116:305-11.
198. Wolfe F, Michaud K. 2004b. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum, 50:1740-51.
199. Zein CO, Zein NN. 2002. Advances in therapy for hepatitis C infection. Microbes Infect, 4:1237-46.
200. Zeltser R, Valle L, Tanck C, et al. 2001. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol, 137:893-9.
201. Zganiacz A, Santosuosso M, Wang J, et al. 2004. TNF-alpha is a critical negative regulator of type 1 immune activation during intracellular bacterial infection. J Clin Invest, 113:401-13.
202. Zhou P, Miller G, Seder RA. 1998. Factors involved in regulating primary and secondary immunity to infection with Histoplasma capsulatum: TNF-alpha plays a critical role in maintaining secondary immunity in the absence of IFN-gamma. J Immunol, 160:1359-68.
203. Zhou T, Mountz JD, Kimberly RP. 2002. Immunobiology of tumor necrosis factor receptor superfamily. Immunol Res, 26:323-36.
204. Zinman B, Hanley AJ, Harris SB, et al. 1999. Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab, 84:27-8.